Опыт применения ритуксимаба при резистентном к терапии фокально-сегментарном гломерулосклерозе у взрослых: серия наблюдений и краткий обзор литературы
https://doi.org/10.36485/1561-6274-2020-24-2-52-59
Аннотация
Об авторах
Н. В. ЧеботареваРоссия
Проф. Чеботарева Наталья Викторовна, д-р мед. наук.
Кафедра внутренних, профессиональных болезней и ревматологии Института клинической медицины им. Н.В.Склифосовского
119991, Москва, ул. Трубецкая, д. 8, стр. 2.
Тел.: 8-905-543-42-50
А. М. Кучиева
Россия
Кучиева Агунда Мэлсовна - врач отделения «искусственная почка» Клиники нефрологии, внутренних и профессиональных болезней УКБ №3.
119991, Москва, ул. Трубецкая, д. 8, стр. 2.
Тел.: 8-906-044-03-97
О. А. Ли
Россия
Ли Ольга Александровна - врач отделения «искусственная почка» Клиники нефрологии, внутренних и профессиональных болезней УКБ №3.
119991, Москва, ул. Трубецкая, д. 8, стр. 2.
Тел.: 8-925-829-16-06
С. В. Рощупкина
Россия
Рощупкина Светлана Васильевна - заведующий отделением нефрологии Клиники нефрологии, внутренних и профессиональных болезней УКБ №3.
119991, Москва, ул. Трубецкая, д. 8, стр. 2.
Тел.: 8-916-614-41-81
В. Цао
Россия
Цао Веньцзин - аспирант кафедры внутренних, профессиональных болезней и ревматологии, Институт клинической медицины им. Н.В.Склифосовского.
119991, Москва, ул. Трубецкая, д. 8, стр. 2.
Тел.: 8-8-916-903-72-38
Список литературы
1. D'Agati V. The many masks of focal segmental glomerulosclerosis. Kidney Int 1994;46(4):1223–1241. doi https://doi.org/10.1038/ki.1994.388
2. Deegens JK, Assmann KJ, Steenbergen EJ et al. Idiopathic focal segmental glomerulosclerosis: a favourable prognosis in untreated patients? Neth J Med 2005;63(10):393–398
3. Rydel JJ, Korbet SM, Borok RZ et al. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis 1995;25(4):534–542. doi:10.1016/0272-6386(95)90120-5
4. Troyanov S, Wall CA, Miller JA, et al. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol 2005; 16:1061–1068. doi: 10.1681/ASN.2004070593
5. Cattran DC, Appel GB, Hebert LA et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 1999; 56:2220–2226. doi:10.1046/j.15231755.1999.00778.x
6. Ponticelli C, Villa M, Banfi G et al. Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis? Am J Kidney Dis 1999; 34:618–625 doi:10.1016/S02726386(99)70384-7
7. Cattran DC, Rao P. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 1998; 32:72–79. doi: 10.1053/ajkd.1998.v32.pm9669427
8. Stirling CM, Mathieson P, Boulton-Jones JM et al. Treatment and outcome of adult patients with primary focal segmental glomerulosclerosis in five UK renal units. QJM 2005; 98:443–449. doi: 10.1093/qjmed/hci072
9. Chun MJ, Korbet SM, Schwartz MM et al. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 2004; 15:2169–2177. doi: 10.1097/01.ASN.0000135051.62500.97
10. Pokhariyal S, Gulati S, Prasad N et al. Duration of optimal therapy for idiopathic focal segmental glomerulosclerosis. J Nephrol 2003; 16:691–696
11. Korbet SM: Primary Focal Segmental Glomerulosclerosis. In: Therapy in Nephrology and Hypertension: A Companion to Brenner and Rector’s The Kidney, edited by Brady RJ, Wilcox CS, 2nd Ed., Philadelphia, W.B. Saunders, 2003:223–236
12. Cattran DC, Appel GB, Hebert LA et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 1999; 56: 2220–2226. doi:10.1046/j.15231755.1999.00778.x
13. Ponticelli C, Rizzoni G, Edefonti A et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1993; 43: 1377–1384. doi: 10.1038/ki.1993.194
14. Cattran DC, Wang MM, Appel G et al. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 2004; 62: 405–411. doi: 10.5414/cnp62405
15. Sharma M, Sharma R, McCarthy ET et al. «The FSGS factor:” enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma. J Am Soc Nephrol 1999;10: 552–561. doi:10.1177/000992289903801009
16. Pollak MR. Focal segmental glomerulosclerosis: Recent advances. Curr Opin Nephrol Hypertens 2008; 17: 138–142. doi: 10.1097/MNH.0b013e3282f5dbe4.
17. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:435– 445. doi: 10.1182/blood.V83.2.435.bloodjournal832435
18. Vallerskog T, Gunnarsson I, Widhe M et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007;122: 62–74. doi:10.1016/j.clim.2006.08.016
19. Bruneau S, Dantal J. New insights into the pathophysiology of idiopathic nephrotic syndrome. Clin Immunol 2009; 133: 13–21
20. Peters HP, van de Kar NC, Wetzels JF. Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: Report of four cases and review of the literature. Neth J Med 2008; 66: 408–415
21. Nakayama M, Kamei K, Nozu K et al. Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol 2008; 23: 481–485. doi:10.1007/s00467-007-0640-x
22. Suri M, Tran K, Sharma AP et al. Remission of steroidresistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab. Int Urol Nephrol 2008; 40: 807–810. doi: 10.1007/s11255-008-9393-0
23. Nozu K, Iijima K, Fujisawa M et al. Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatric Nephrology 2005; 11 (20): 1660–1663. doi:10.1007/s00467005-2013-7
24. Pescovitz MD, Book BK, Sidner RA. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. New England Journal of Medicine 2006; 18 (354):1961–1963. doi: 10.1056/NEJMc055495
25. Hristea D, Hadaya K, Marangon N et al. Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transplant International 2007; 1 (20):102–105. doi:10.1111/j.14322277.2006.00395.x
26. Gossmann J, Scheuermann EH, Porubsky S et al. Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosis. Transplant International 2007; 6(20): 558–562. doi:10.1111/j.1432-2277.2007.00477.x
27. Sugiura H, Takei T, Itabashi M et al. Effect of single dose rituximab on primary glomerular diseases. Nephron Clin Pract 2011; 117:98–105. doi: 10.1159/000319656.
28. Ochi A, Takei T, Nakayama K et al. Rituximab Treatment for Adult Patients with Focal Segmental Glomerulosclerosis. Intern Med 2012; 51: 759–762. doi: 10.2169/internalmedicine.51.6854
29. El-Reshaid K, Sallam HT, Hakim AA et al. Rituximab in Treatment of Idiopathic Glomerulopathy. Saudi J Kidney Dis Transpl 2012;23(5):973–978. doi: 10.4103/1319-2442.100878.
30. Kong WY, Swaminathan R, Irish A. Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature. Int Urol Nephrol 2013; 45:795–802. doi: 10.1007/s11255-012-0206-0.
31. Roccatello D, Sciascia S, Rossi D. et al. High-Dose Rituximab Ineffective for Focal Segmental Glomerulosclerosis: A Long-Term Observation Study. Am J Nephrol 2017;46:108–113 doi: 10.1159/000477944
32. Varwani MH, Sokwala A. Treatment of Steroid-Resistant Focal Segmental Glomerulosclerosis with Rituximab: A Case Report and Review of Literature. Saudi J Kidney Dis Transpl 2017;28(5):1175–1179. doi: 10.4103/1319-2442.215133.
33. Dahan K, Debiec H, Plaisier E et al. Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. J Am Soc Nephrol 2017; 28: 348–358. doi: 10.1681/ASN.2016040449.
34. Ruggenenti P, Ruggiero B, Cravedi P et al. Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome. J Am Soc Nephrol 2014; 25: 850–863. doi: 10.1681/ASN.2013030251
35. Fernandez-Fresnedo G, Segarra A, Gonzalez E et al. Rituximab Treatment of Adult Patients with Steroid-Resistant Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol 2009; 4: 1317–1323. doi: 10.2215/CJN.00570109
36. Fornoni A, Sageshima J, Wei C et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 2011;3(85):85ra46. doi: 10.1126/scitranslmed.3002231.
37. Iharada A, Kaneko K. Tsuji S et al. Increased nitric oxide production by T- and Bcells in idiopathic nephrotic syndrome. Pediatric Nephrology 2009; 5 (29): 1033–1038. doi: 10.1007/s00467-008-1092-7
38. Dantal J, Godfrin Y, Koll R et al. Antihuman immunoglobulin anity immunoadsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome. Journal of the American Society of Nephrology 1998: 9 (9): 1709–1715
Рецензия
Для цитирования:
Чеботарева Н.В., Кучиева А.М., Ли О.А., Рощупкина С.В., Цао В. Опыт применения ритуксимаба при резистентном к терапии фокально-сегментарном гломерулосклерозе у взрослых: серия наблюдений и краткий обзор литературы. Нефрология. 2020;24(2):52-59. https://doi.org/10.36485/1561-6274-2020-24-2-52-59
For citation:
Chebotareva N.V., Kuchieva A.M., Lee O.A., Roshchupkina C.V., Cao V. Experience of application of rituximab with resistant focal-segmental glomerulosclerosis in adults: a series of observations and a brief review of literature. Nephrology (Saint-Petersburg). 2020;24(2):52-59. (In Russ.) https://doi.org/10.36485/1561-6274-2020-24-2-52-59